Results 201 to 210 of about 159,104 (312)

Lymphoma, multiple myeloma and leukaemia incidence in regions of Belarus most heavily contaminated by the Chernobyl accident

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3161-3172, 15 June 2026.
What's new? The 1986 Chernobyl accident led to widespread radioactive contamination across parts of Europe, with elevated childhood leukaemia rates observed in heavily affected areas of Ukraine. Data on long‐term haematological and other non‐thyroid cancer risk in the general population in heavily contaminated regions, however, remain limited.
Ljubica Zupunski   +10 more
wiley   +1 more source

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes

open access: yesAmerican Journal of Hematology, Volume 101, Issue 6, Page 1388-1397, June 2026.
ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth.
Arushi Khurana   +14 more
wiley   +1 more source

The Atypical and Suspicious for Malignancy Categories of the WHO Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Review of their Diagnostic Utility, Limitations, and Clinical Impact

open access: yesDiagnostic Cytopathology, Volume 54, Issue 6, Page 449-460, June 2026.
ABSTRACT Background Fine‐needle aspiration biopsy (FNAB) is the preferred first‐line diagnostic tool for evaluating lymphadenopathy due to its minimally invasive nature and cost‐effectiveness. However, cytopathological interpretation of lymph node FNAB remains challenging because of the wide morphological spectrum of lymphoid lesions.
Immacolata Cozzolino   +5 more
wiley   +1 more source

Treatment Outcomes and Overall Survival of Patients With B‐Cell Prolymphocytic Leukemia

open access: yeseJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction B‐cell prolymphocytic leukemia (B‐PLL) is a rare, aggressive leukemic B‐cell malignancy historically associated with poor outcomes and recently reclassified in the WHO Fifth Edition but retained as a distinct entity in the ICC.
Daniel A. Ermann   +6 more
wiley   +1 more source

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms. [PDF]

open access: yesCurr Hematol Malig Rep
Hanna C   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy